CRX.L Regulatory News (CRX)

17 Aug 2005 07:00

Cyprotex PLC17 August 2005 Press Release 17 August 2005 Cyprotex PLC Cyprotex enters significant long-term contract with Sepracor Cyprotex PLC (LSE:CRX), the drug discovery technology and information company,is pleased to announce that it has entered into a significant long-term contractfor Cyprotex's integrated Cloe offering with the major US-based pharmaceuticalcompany, Sepracor Inc. Commenting on the agreement, Robert Morrisson Atwater, Chief Executive Officerof Cyprotex PLC, said: "This is Cyprotex's first major US partnership whichshows that our technologies, expertise and general approach are attracting awider audience. This deal is clear demonstration that Cyprotex is gaining welldeserved recognition as a valuable partner in drug discovery." About Cyprotex From its Cloe Screen(R) suite of assays, Cyprotex generates detailed profiles ofa customer's compounds to include their absorption, distribution, metabolism,excretion and toxicity (ADME) properties. A partnership is structured withcustomers to provide essential early evaluation of compounds to supportdecision-making on the selection of lead series to take forward, in addition toproviding follow-up experimental support for further investigating potentialliabilities on smaller groups of compounds. This partnership will also ensurethe steady supply of critical information for guiding a customer's leadoptimisation and compound selection for clinical trials. Cyprotex provides arapid turnaround of core compound property information on a weekly basisalongside its customer's chemistry design and lead optimisation efforts.Customers also use Cyprotex's Cloe PK(R) software to integrate and interpret thedata - by predicting how these properties combine to affect the exposure levelof compounds in the blood and major organs in the body over time. - Ends - For further information:Cyprotex PLCRobert Morrisson Atwater, Chief Executive Officer Tel: +44 (0) 1625 505 100ir@cyprotex.com www.cyprotex.com Media enquiries:Abchurch CommunicationsHeather Salmond / Samantha Robbins Tel: +44 (0) 20 7398 7700samantha.robbins@abchurch-group.com www.abchurch-group.com Notes to editors Cyprotex plc - www.cyprotex.com Cyprotex is a specialist provider of experimental and computational capabilitiesto support ADME/toxicity and pharmacokinetics assessment for drug discoverypartners. Its core products include the Cloe Screen(TM) in vitro ADME/toxicityservice, and Cloe PK(TM) - a pharmacokinetics prediction system which integratescore ADME and physicochemical compound data to predict compound levels in plasmaand major organs in the body. This unique combination of technologies is aimedat improving pharmaceutical productivity by improving the quality of compoundlibraries and drug candidates progressing through the drug pipeline. Cyprotexis based in the UK and is listed on the London Stock Exchange (CRX). This information is provided by RNS The company news service from the London Stock Exchange